Susannah Gray

Susannah Gray currently works at Theravance Biopharma, Inc., as Chairman from 2024, The German Marshall Fund of United States, as Director, StreetSquash, as Director, Biosplice Therapeutics, Inc., as Director, 4D Molecular Therapeutics, Inc., as Independent Director from 2020, Susan G.
Komen Foundation, as Director, Biosplice LLC, as Director, Colby College Museum of Art, as Director, Maravai Lifesciences Holdings, Inc., as Independent Director from 2020, Morphic Therapeutic, Inc., as Director from 2021, Maravai Life Sciences, Inc., as Director from 2020, and Wesleyan University, as Trustee.
Ms. Gray also formerly worked at Merrill Lynch & Co., Inc., as Managing Director, Susan G.
Komen for the Cure, as Director from 2019 to 2022, Apria, Inc., as Independent Director from 2021 to 2022, Morphic Holding, Inc., as Independent Director from 2021 to 2024, CIBC World Markets Corp.
(Old), as Analyst from 2002 to 2004, RP Management LLC, as Executive Vice President-Finance & Strategy in 2019, and Royalty Pharma Management LLC, as Executive Vice President-Finance & Strategy from 2018 to 2019.
Ms. Gray received her undergraduate degree in 1982 from Wesleyan University and Masters Business Admin degree in 1990 from Columbia Business School.